Infliximab (RemicadeR) is an IgG1 chimeric monoclonal antibody against membrane-boundand soluble TNF-a and is administered as an intravenous infusion most commonly atweeks 0, 2, and 6 (induction), and then every eight weeks(maintenance).[10] Inuveitis patients, infliximab may be given at a low (<10 mg/kg), moderate (≥10–15 mg/kg), or a high (≥15–20 mg/kg) dose.[11] Efficacy of infliximab has been widely studied in treatmentof uveitis associated with Behcet's disease (BD),[12,13,14,15,16,17] juvenile idiopathic arthritis (JIA),[18,19,20,21,22]sarcoidosis,[23] and otherNIUs. This evidence concerns the gene TNF and Behcet disease.